89Zr-Bevacizumab PET Visualizes Disease Manifestations in Patients with von Hippel–Lindau Disease
نویسندگان
چکیده
منابع مشابه
89Zr-Bevacizumab PET Visualizes Disease Manifestations in Patients with von Hippel-Lindau Disease.
UNLABELLED Patients with von Hippel-Lindau disease (VHL) are at risk to develop multiple tumors. The growth of lesions is unpredictable, and regular surveillance is critical for early treatment to control local damage. Vascular endothelial growth factor A (VEGF-A) produced locally is supposed to play an important role in development of disease manifestations and is a target for antiangiogenic t...
متن کامل89Zr-bevacizumab PET imaging in primary breast cancer.
UNLABELLED Vascular endothelial growth factor (VEGF)-A is overexpressed in most malignant and premalignant breast lesions. VEGF-A can be visualized noninvasively with PET imaging and using the tracer (89)Zr-labeled bevacizumab. In this clinical feasibility study, we assessed whether VEGF-A in primary breast cancer can be visualized by (89)Zr-bevacizumab PET. METHODS Before surgery, breast can...
متن کاملPulmonary manifestations in von Recklinghausen's disease.
Von Recklinghausen's disease, neurofibromatosis type 1 (NF1), is a commonautosomal disorder characterized by multiple neurofibromas, cafe au lait spots, and Lisch nodules of the iris with a variable clinical expression. This disorder appears to affect all races, with a prevalence estimated to be 1 in 3,000 live births. The NF1 gene is located in 17ql 1.2. However, due to the high mutation rate ...
متن کامل89Zr-bevacizumab PET visualizes heterogeneous tracer accumulation in tumor lesions of renal cell carcinoma patients and differential effects of antiangiogenic treatment.
UNLABELLED No validated predictive biomarkers for antiangiogenic treatment of metastatic renal cell carcinoma (mRCC) exist. Tumor vascular endothelial growth factor A (VEGF-A) level may be useful. We determined tumor uptake of (89)Zr-bevacizumab, a VEGF-A-binding PET tracer, in mRCC patients before and during antiangiogenic treatment in a pilot study. METHODS Patients underwent (89)Zr-bevaciz...
متن کامل89Zr-cetuximab PET imaging in patients with advanced colorectal cancer
Monoclonal antibodies (mAbs) against the epidermal growth factor receptor (EGFR) are used in the treatment of advanced colorectal cancer (mCRC). Approximately 50% of patients benefit despite patient selection for RAS wild type (wt) tumors. Based on the hypothesis that tumor targeting is required for clinical benefit of anti-EGFR treatment, biodistribution and tumor uptake of (89)Zr-cetuximab by...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Nuclear Medicine
سال: 2016
ISSN: 0161-5505,2159-662X
DOI: 10.2967/jnumed.115.167643